Martin Mackay, Ph.D.
Position: Executive Vice President, Global Head of Research and Development
Joined Alexion: 2013
Prior to Alexion: President of R&D at Astra Zeneca, Head of Pfizer Pharmatherapeutics, R&D
Education: Honours Degree in Microbiology from Heriot-Watt University, Scotland, and a Ph.D. in Molecular Genetics from the University of Edinburgh, Scotland.
Dr. Mackay has more than 30 years of experience in drug discovery and development on a global scale. He is currently focused on significantly expanding Alexion’s global research and development organization, with a goal of accelerating the simultaneous development of multiple life-transforming drug candidates in debilitating and life-threatening ultra-rare disorders across a range of therapeutic areas
Prior to joining Alexion, Dr. Mackay served as President, Research and Development at AstraZeneca, where he led all R&D functions worldwide, including discovery research, clinical development, regulatory affairs and key related R&D functions. He also held positions of increasing responsibility at Pfizer, rising to the position of President, Head of Pfizer Pharmatherapeutics, R&D, where he oversaw all aspects of small molecule discovery and development across multiple therapeutic areas. Earlier in his career, Dr. Mackay worked in the CIBA organization (now Novartis) and held positions within academia.